Splash Begins Expansion Phase of SPL-108 Trial for Ovarian Cancer Patients

Splash Begins Expansion Phase of SPL-108 Trial for Ovarian Cancer Patients
Splash Pharmaceuticals has successfully completed the safety stage of its Phase 1 trial testing a combination of SPL-108 and chemotherapy in platinum-resistant ovarian cancer patients, the company announced in a press release. Taking place at Rutgers Cancer Institute of New Jersey, the open-label trial (NCT03078400) is now recruiting participants into its dose escalation phase. “The target, mechanism of action, and clinical data all support the idea of further testing SPL-108 and paclitaxel in ovarian cancer patients,” David Nelson, president and CEO of Splash, said in the release. “We believe that SPL-108 will be synergistic with other anti-tumor drugs as well and could be applicable in many different tumor types including breast and endometrial cancers. We are pleased that the first patients have cleared this critical safety hurdle." While SPL-108's mechanism of action is not fully known, researchers believe it works by targeting a surface protein, called CD44,
Subscribe or to access all post and page content.